Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $32.7143.

A number of research firms have issued reports on AVTX. Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Avalo Therapeutics in a research note on Thursday, January 15th. BTIG Research reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Avalo Therapeutics in a research note on Monday, September 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th.

Avalo Therapeutics Stock Performance

NASDAQ AVTX opened at $15.75 on Monday. The stock has a fifty day moving average of $17.63 and a 200-day moving average of $13.43. The stock has a market capitalization of $291.53 million, a P/E ratio of -2.94 and a beta of 0.84. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.52). Equities research analysts forecast that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Avalo Therapeutics

Several hedge funds have recently added to or reduced their stakes in AVTX. BIT Capital GmbH bought a new position in Avalo Therapeutics during the third quarter worth about $25,000. PFS Partners LLC raised its position in shares of Avalo Therapeutics by 100.0% in the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after acquiring an additional 1,000 shares during the period. Quadrature Capital Ltd bought a new position in Avalo Therapeutics during the 2nd quarter worth approximately $55,000. Boothbay Fund Management LLC bought a new position in Avalo Therapeutics during the 2nd quarter worth approximately $56,000. Finally, Dimensional Fund Advisors LP acquired a new position in Avalo Therapeutics during the third quarter valued at approximately $143,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.